Alnylam Pharmaceuticals (ALNY) - Net earnings per share (EPS TTM)

Symbol and logo of brand alnylam.com (ALNY)

By leveraging a closed RNA interference ecosystem, Alnylam Pharmaceuticals (ALNY) creates high switching costs for alternative treatments. The TTM net income per share trend reflects balanced demand during periods of market volatility, with 19.84 representing the current level of this metric. This stability is further supported by a workforce of leading geneticists and streamlined international distribution channels for innovative drugs.

ALNY (alnylam.com) Earnings per share for the last 12 months history from 07/04/2022 to 11/17/2026

Comprehensive metric breakdowns and analytics for Alnylam Inc. (ALNY)

General company analysis:alnylam.com (ALNY)
Mass-produced product of Alnylam Pharmaceuticals, Inc.

Identifying fundamentally resilient assets requires an analysis of real returns, measured by the trailing 12-month earnings per share (EPS), which divides the company's bottom line by the total number of outstanding shares. For Alnylam Pharmaceuticals (ALNY), which possesses significant pricing power in the RNA interference segment, the trend of this metric confirms the quality of earnings and the predictability of cash flows, allowing the trailing 12-month earnings per share to distinguish objective growth from market speculation.

Competitors of Alnylam Pharmaceuticals (ALNY)

VRTX: Net earnings per share for the last 12 months|Earnings per one share for the last 12 months INSM|UTHR: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months BioMarin Pharma (BMRN)|BBIO (BridgeBio) - Net earnings per share (EPS TTM)|BGM: Earnings per share for the trailing year|Net earnings per share for the last 12 months COGT (Cogent Biosciences, Inc.)|XERS (Xeris Biopharma Holdings, Inc.) - Earnings per share for the trailing year|Earnings per share for the last twelve months Keros Therapeutics, Inc. KROS|ARCT (Arcturus Pharma) - Earnings per one share for the last 12 months|Eton Pharmaceuticals - Net earnings per share (EPS TTM)|Earnings per share for the trailing year KMDA (Kamada Ltd.)|FULC: Net earnings per share (EPS TTM)|Abeona (ABEO) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months mereobiopharma.com|Net earnings per share for the last 12 months Protalix (PLX)|Earnings per share for the last twelve months Pliant Therapeutics Inc (PLRX)|Net earnings per share for the last 12 months Applied Therapeutics, Inc. APLT|Net earnings per share (EPS TTM) RNTX (aileronrx.com)|Net earnings per share (EPS TTM) Gelteq Limited Inc GELS|Aytu BioPharma, Inc. - Net earnings per share (EPS TTM)|chemomab.com (CMMB) - Net earnings per share for the last 12 months|SRx Health (SRXH) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Polyrizon Ltd. (PLRZ)|Net earnings per share for the last 12 months AEZS|Net earnings per share for the last 12 months Cyclo Therapeutics Inc. (CYTH)|Net earnings per share for the last 12 months INZY (inozyme.com)|RPHM - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) CSCI (cosciensbio.com)